Carrie Brownstein - Feb 1, 2023 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role
Chief Medical Officer
Signature
/s/ Andrea Paul, attorney-in-fact for Carrie Brownstein
Stock symbol
ZNTL
Transactions as of
Feb 1, 2023
Transactions value $
$0
Form type
4
Date filed
2/1/2023, 06:06 PM
Previous filing
Oct 3, 2022
Next filing
May 31, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZNTL Common Stock Award $0 +16.3K +16.31% $0.00 116K Feb 1, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZNTL Stock Option (Right to Buy) Award $0 +23.7K $0.00 23.7K Feb 1, 2023 Common Stock 23.7K $23.65 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date.
F2 The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date.